Skip to content
Menu

Canaccord Genuity Maintains Buy on Nektar Therapeutics, Lowers Price Target to $149

Benzinga Newsdesk 1 day ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Canaccord Genuity analyst Edward Nash maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and lowers the price target from $153 to $149.

Canaccord Genuity analyst Edward Nash maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and lowers the price target from $153 to $149.

Read at benzinga.com